Argenx SE (NASDAQ:ARGX) Cuts Program, Shifts Focus; Near-Term Momentum Stabilizes
![]() |
Argenx announced a discontinuation of a Phase 3 program that reshapes clinical priorities while technical indicators show emerging bullish momentum against an over-valued baseline. |










